株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

遺伝子検査の世界市場:産業分析、市場見通し

Global Genetic Testing Market - Industry Analysis and Market Forecast (2017 - 2022)

発行 Mordor Intelligence LLP 商品コード 319191
出版日 ページ情報 英文 205 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.18円で換算しております。
Back to Top
遺伝子検査の世界市場:産業分析、市場見通し Global Genetic Testing Market - Industry Analysis and Market Forecast (2017 - 2022)
出版日: 2017年01月01日 ページ情報: 英文 205 Pages
概要

当レポートでは、世界の遺伝子検査市場について調査分析を行い、市場概要、市場因子、セグメンテーション別考察、地域別分析、競合状況、主要企業のプロファイルなどについてまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 主な影響因子

第5章 市場概要と産業動向

  • 現在の市場シナリオ
  • ポーターのファイブフォース分析

第6章 市場の成長因子・成長阻害因子・機会・課題の分析

  • 市場発展因子
  • 市場発展阻害因子
  • 市場機会
  • 市場課題

第7章 遺伝子検査市場の分類

  • 種類別
  • 疾患別
  • 技術別
  • 地域別

第8章 競合情勢

  • M&A
  • 合意・競合・提携
  • 新製品の発売

第9章 企業プロファイル

第10章 アナリストによる投資機会の見通し

第11章 市場の将来見通し

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

The global genetic testing market accounted for USD 3.8 Billion in 2015 and is estimated to reach USD 4.23 billion in 2016. Growing at a moderately high CAGR of 9.7%, the market value is expected to reach USD 6.7 billion by 2021.

*Some values in the chart may be randomized. Actual data available on report purchase.

In the recent years, with advancements in science and technology, genetic testing has grown to become one of the most important markets in healthcare. Genetic testing allows diagnosis of a disease after its onset, as well as predicting the risk of acquiring a certain disease. There are a number of government initiatives that are being taken to bring about awareness and educate people about the benefits of genetic testing.

Global Genetic Testing Market- Market Segmentation

The global genetic testing market is segmented by type, disease, technology and geography.

By type, the market is segmented into carrier testing, diagnostic testing, new-born screening, predictive & pre-symptomatic testing and prenatal testing.

The new-born screening market accounted for the highest market share in 2015 and is projected to reach USD XX million in 2016 and USD XX billion by 2021, at a CAGR of XX% during the forecast period. However, the carrier testing market is expected to grow at the highest CAGR of XX% from 2016 to 2021.

*Some values in the chart may be randomized. Actual data available on report purchase.

By disease, the market is segmented into Alzheimer's, cancer, cystic fibrosis, sickle cell anemia, Duchenne's muscular dystrophy, thalassemia, and Huntington's disease.

The cancer testing market holds the largest share and is projected to reach USD XX million in 2016 and USD XX billion by 2021. The Alzheimer's disease testing market holds the second largest share and is estimated to reach USD XX million in 2016.

*Some values in the chart may be randomized. Actual data available on report purchase.

By technology, the market is segmented into cytogenetic testing, molecular testing, and biochemical testing markets.

The molecular testing market holds the largest share, estimated to reach USD XX billion in 2016. However, the cytogenetic testing market is expected to grow at the highest CAGR of XX% during the forecast period.

*Some values in the chart may be randomized. Actual data available on report purchase.

By technology, the market is segmented into cytogenetic testing, molecular testing, and biochemical testing markets.

The molecular testing market holds the largest share, estimated to reach USD XX billion in 2016. However, the cytogenetic testing market is expected to grow at the highest CAGR of XX% during the forecast period.

Some of the key players in the market are:

  • Transgenomic, Inc.
  • 23 & Me
  • Sequenom, Inc.
  • Abbott Molecular
  • Biocartis SA
  • Illumina Inc.
  • Luminex Corporation

Key Deliverables in the Study

  • Market analysis for the genetic testing market, with region-specific assessments and competition analysis on the global and regional scales.
  • Market definition along with the identification of key drivers and restraints.
  • Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
  • Extensively researched competitive landscape section with profiles of major companies along with their market share.
  • Identification and analysis of the macro and micro factors that affect the genetic testing market on both global and regional scale.
  • A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
  • A wide-ranging knowledge and insight about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.
  • Insights on the major countries/regions where this industry is growing and also to identify the regions that are still untapped.

Table of Contents

1. Introduction

  • 1.1. Study Deliverables
  • 1.2. Market Definition
  • 1.3. Sizing Units
  • 1.4. Base Currency
  • 1.5. Review and Forecast Period Years
  • 1.6. General Study Assumptions

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Analysis Methodology
  • 2.3. Econometric Forecast Model
  • 2.4. Research Assumptions

3. Executive Summary

4. Key Inferences

5. Market Overview and Industry trends

  • 5.1. Current Market Scenario
  • 5.2. Porter's Five Forces Analysis
    • 5.2.1. Bargaining Power of Suppliers
    • 5.2.2. Bargaining Power of Consumers
    • 5.2.3. Threat of New Entrants
    • 5.2.4. Threat of Substitute Products and Services
    • 5.2.5. Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges (DROC) Analysis

  • 6.1. Market Drivers
    • 6.1.1. Emphasis on Early Disease Detection and Prevention
    • 6.1.2. Growing Demand for Personalized Medicine
    • 6.1.3. Increasing Application of Genetic Testing in Oncology
  • 6.2. Market Restraints
    • 6.2.1. High Costs of Genetic Testing Market
    • 6.2.2. Potentially Adverse Personal or Societal Consequences
  • 6.3. Market Opportunities
    • 6.3.1. Genetic Counseling
    • 6.3.2. Genetic Nursing
  • 6.4. Market Challenges
    • 6.4.1. Lack of Regulation

7. Global Genetic Testing Market Segmentation

  • 7.1. By Type
    • 7.1.1. Carrier Testing
    • 7.1.2. Diagnostic Testing
    • 7.1.3. New Born Screening
    • 7.1.4. Predictive & Presymptomatic Testing
    • 7.1.5. Prenatal Testing
  • 7.2. By Diseases
    • 7.2.1. Alzheimer's Diseases
    • 7.2.2. Cancer
    • 7.2.3. Cystic Fibrosis
    • 7.2.4. Sickle Cell Anemia
    • 7.2.5. Duchenne's Muscular Dystrophy
    • 7.2.6. Thalassemia
    • 7.2.7. Huntington's disease
    • 7.2.8. Others
  • 7.3. By Technology
    • 7.3.1. Cytogenetic testing
    • 7.3.2. Biochemical testing
    • 7.3.3. Molecular Testing
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. USA
      • 7.4.1.2. Canada
      • 7.4.1.3. Mexico
    • 7.4.2. Europe
      • 7.4.2.1. Germany
      • 7.4.2.2. UK
      • 7.4.2.3. France
      • 7.4.2.4. Italy
      • 7.4.2.5. Spain
      • 7.4.2.6. BENELUX
      • 7.4.2.7. Scandinavia
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China
      • 7.4.3.2. India
      • 7.4.3.3. Japan
      • 7.4.3.4. Australia & New Zealand
      • 7.4.3.5. South Korea
      • 7.4.3.6. Rest of APAC
    • 7.4.4. Middle East & Africa
      • 7.4.4.1. GCC
      • 7.4.4.2. Egypt
      • 7.4.4.3. South Africa
      • 7.4.4.4. Rest of Middle East & Africa
    • 7.4.5. Latin America
      • 7.4.5.1. Brazil
      • 7.4.5.2. Argentina
      • 7.4.5.3. Rest of Latin America

8. Competitive Landscape

  • 8.1. Mergers & Acquisitions
  • 8.2. Agreements, Collaborations & Partnerships
  • 8.3. New Product Launches

9. Company Profiles

  • 9.1. 23 & me
  • 9.2. Abbott Molecular
  • 9.3. Ariosa Diagnostics, Inc.
  • 9.4. Biocartis Sa
  • 9.5. Cepheid
  • 9.6. Illumina, Inc
  • 9.7. Luminex Corporation
  • 9.8. Sequenom, Inc
  • 9.9. Transgenomic, Inc

10. Analyst Outlook for Investment Opportunities

11. Future Outlook of the Market

Back to Top